Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Use of halogenated thymidine analogs as clinical radiosensitizers: rationale, current status, and future prospects: non-hypoxic cell sensitizers

Journal Article · · Int. J. Radiat. Oncol., Biol. Phys.; (United States)
The halogenated pyrimidine analogs, bromodeoxyuridine (BUdR) and iododeoxyuridine (IUdR) have been recognized as potential clinical radiosensitizers for over two decades. In vivo and in vitro experimental studies document that radiosensitization is directly dependent on the amount of thymidine replacement in DNA by these analogs. Based on recent in vivo and clinical pharmacology studies on continuous intravenous infusions of these drugs, clinical trials are underway evaluating the potential of radiosensitization in high grade gliomass and other poorly radioresponsive tumors using the technically safer intravenous route of administration. In this paper, the authors review the basic strategy for the use of these analogs, the ongoing clinical trials and the potential areas for future experimental and clinical studies.
Research Organization:
National Cancer Inst., Melbourne, Australia
OSTI ID:
6354644
Journal Information:
Int. J. Radiat. Oncol., Biol. Phys.; (United States), Journal Name: Int. J. Radiat. Oncol., Biol. Phys.; (United States) Vol. 10:8; ISSN IOBPD
Country of Publication:
United States
Language:
English

Similar Records

Halogenated pyrimidines as radiosensitizers in the treatment of glioblastoma multiforme
Journal Article · Thu Oct 01 00:00:00 EDT 1987 · Am. J. Clin. Oncol.; (United States) · OSTI ID:5849649

Continuous intravenous infusions of bromodeoxyuridine as a clinical radiosensitizer
Journal Article · Mon Oct 01 00:00:00 EDT 1984 · J. Clin. Oncol.; (United States) · OSTI ID:5615268

DIRECT AND INDIRECT INACTIVATION OF BACTERIOPHAGE T6 CONTAINING HALOGENATED DNA
Journal Article · Tue Dec 31 23:00:00 EST 1963 · RAdiation Res. · OSTI ID:4132430